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Abstract
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Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open-label, phase 2 study
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(NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated
acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Patients received
glasdegib 100 mg orally, once daily in continuous 28-day cycles from day −3, with intravenous
cytarabine 100 mg/m2 on days 1-7 and daunorubicin 60 mg/m2 on days 1-3. Patients in remission then received consolidation therapy (2-4 cycles of cytarabine 1 g/m2 twice daily on days
1, 3, 5 of each cycle), followed by maintenance glasdegib (maximum 6 cycles). Primary endpoint
was complete remission (CR) in patients aged ≥55 years. Secondary endpoints included overall
survival (OS), safety and outcome by mutational status. Patients had a median (range) age of
64.0 (27-75) years, 60.0% were male, and 84.5% were white. In 69 evaluable patients, 46.4%
(80% confidence interval [CI]: 38.7-54.1) achieved investigator-reported CR. Among patients
≥55 years old (n = 60), 40.0% (80% CI 31.9-48.1) achieved CR. Among all 69 patients, median
OS was 14.9 (80% CI 13.4-19.3) months, with 12-month survival probability 66.6% (80% CI
58.5-73.4). The most common treatment-related adverse events (≥50% patients) were diarrhea
and nausea. There were no significant associations between mutational status (12 genes) and
clinical response, suggesting potential benefit across diverse molecular profiles. Glasdegib plus
cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with
untreated AML or high-risk MDS. A randomized phase 3 trial of glasdegib in combination with
chemotherapy (7 + 3 schedule) is ongoing.
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The objectives of this phase 2 study were to evaluate the efficacy

1 | I N T RO D UC T I O N

of glasdegib when administered in combination with standard cytaraAcute myeloid leukemia (AML) is the most common acute leukemia in

bine/daunorubicin induction (on a 7 + 3 schedule) and consolidation,

adults, and incidence correlates with age. Older (>60 years) patients

followed by maintenance therapy, in patients with previously

with AML typically have poorer prognoses and outcomes compared

untreated AML or high-risk MDS.

with younger patients, with response rates ≤50% to conventional
treatments frequently reported, and few patients survive >2 years.1–8
The Hedgehog (Hh) signaling pathway is critical for embryogene9–11

sis, and is typically repressed after birth.

In normal tissue, Hh acti-

vation is dependent on the transmembrane protein Smoothened
(SMO).9–11 Hh ligand-binding results in the Patched receptor releasing
SMO, which then moves from an intracellular vesicle into the primary
cilium.9–12 Activated glioma (GLI)-associated proteins then translocate
to the nucleus and promote target gene transcription.9–12 Aberrations
in Hh signaling have been identified in a variety of human leukemias
and particularly in leukemia stem cells.

2 | METHODS

10–14

Upregulation of Hh

pathway components is implicated in chemoresistant AML cell lines,
and pharmacologic inhibition of the Hh pathway results in decreased
multidrug resistance and P-glycoprotein expression in these

2.1 | Study design
This was an open-label, phase 2, multicenter study of glasdegib in
combination with cytarabine/daunorubicin in patients with previously
untreated AML or high-risk MDS. The study was conducted globally
at 25 centers. The study was approved by an institutional review
board or independent ethics committee at each study center, and was
conducted in accordance with the study protocol, International Ethical
Guidelines for Biomedical Research Involving Human Subjects (2002),
Guidelines for Good Clinical Practice (1996), the Declaration of Hel-

cells.10–12,15,16 Studies in transgenic mouse models of leukemia have

sinki (1996 and 2008), and applicable local regulatory requirements

also supported a role for Hh signaling in disease progression.17–19 In

and laws. All patients provided written informed consent. The study is

addition, overexpression of GLI1 is associated with relapse, drug

registered on ClinicalTrials.gov (NCT01546038; Pfizer study number

resistance, poor remission and reduced overall survival (OS) in

B1371003).

patients with AML.

10,11

Glasdegib (PF-04449913) is an oral, small molecule inhibitor of
the Hh pathway component SMO.20–25 Glasdegib prevents the translocation of SMO into primary cilia and prevents SMO-mediated activation of downstream Hh targets.12,23,26 Previous studies have
reported glasdegib inhibition of SMO reduced the expression of key
intracellular leukemia stem cell regulators (eg, GLI2) and enhanced cell
cycle transit.23,27 These results and preclinical evidence that Hh inhibi10,11,14,28

tion may sensitize cells to cytarabine or azacitidine

provided

rationale for evaluating glasdegib in combination with chemotherapeutic agents to reduce resistance and leukemic persistence or

2.2 | Patients
Patients ≥18 years old were registered using an Interactive Registration System. The study was designed specifically for older (≥55 years)
patients; however, up to 10 patients aged <55 years were permitted
to enter the study for exploratory purposes. After these 10 patients
were enrolled, enrollment was restricted to patients aged ≥55 years.
Patients had newly diagnosed or previously untreated AML (de novo
AML, AML evolving from an antecedent hematologic disease or MDS,
or AML secondary to previous cytotoxic or radiation therapy) or
refractory anemia with excess blast 2 high-risk MDS, according to the

progression.
In an open-label, phase 1 study (ClinicalTrials.gov, NCT00953758)

World Health Organization 2008 classification.

of glasdegib in adult patients with myeloid malignancies who were

Patients with MDS, as well as those with AML arising from MDS

refractory, resistant, or intolerant to previous agents, treatment was

or other antecedent hematologic disease, may have had one prior reg-

generally well tolerated and some preliminary clinical activity was

imen with a commercially available agent(s) for the treatment of prior

observed.25 The most common treatment-related adverse events (AEs)

hematologic disease. Prior therapy for AML was not permitted.

included dysgeusia (28%), decreased appetite (19%) and alopecia

Patients had to have adequate organ function, with an Eastern Coop-

25

(15%).

None of the 15 deaths reported were considered to be
25

treatment-related.

In an open-label, phase 1B study (NCT01546038),

erative Oncology Group performance status <2 in order to receive
intensive chemotherapy.

glasdegib was well tolerated in combination with low-dose cytarabine

Patients were excluded if they had any of the following: t

(LDAC) or decitabine, or in combination with cytarabine/daunorubicin,

(9;22) cytogenetic translocation, acute promyelocytic leukemia,

29

in patients with AML or high-risk myelodysplastic syndromes (MDS).

hyperleukocytosis (leukocytes ≥30 × 109 /L) at screening (hydroxy-

The most common treatment-related nonhematologic AEs were mostly

urea or leukopheresis were allowed before and up to 1 week after

grade 1-2. The recommended phase 2 dose was established as 100 mg

first dose of glasdegib for control of rapidly progressing leukemia),

daily in combination with standard chemotherapy.29 In the phase

or known active leukemia in the central nervous system. Other

2 portion of the study (NCT01546038) in previously untreated

exclusion criteria included: serum creatinine >1.3 mg/dL, severe

patients with AML or high-risk MDS, glasdegib plus LDAC improved

cardiac disease (eg, left-ventricular ejection fraction <45% by mul-

OS compared with LDAC alone; the improvement was consistent

tiple gated acquisition or echocardiography at screening), or a

among subgroups.

26

Glasdegib plus LDAC was associated with an

acceptable safety profile.

26

cumulative anthracycline dose equivalent of ≥250 mg/m2 of daunorubicin or ≥125 mg/m2 of idarubicin.
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2.3 | Study treatment

2.4.3 | Pharmacokinetics

Patients received glasdegib 100 mg orally, once daily in continuous

Patient blood samples were collected for pharmacokinetic (PK) analy-

28-day cycles. Patients received induction with glasdegib from day −3

sis of glasdegib at protocol-defined time points. Glasdegib plasma pre-

in combination with intravenous daunorubicin 60 mg/m (on days

dose concentration (Ctrough) levels were estimated based on sparse PK

1-3) and continuous intravenous cytarabine 100 mg/m2 (on days 1-7).

sampling data. Additional details of PK analyses can be found in the

If required, a second induction cycle could be initiated at the same

Supporting Information Materials.

2

doses as early as day 21 of cycle 1. Patients achieving complete remission (CR) were eligible to receive consolidation therapy with 2-4
cycles of cytarabine 1 g/m2 twice daily on days 1, 3 and 5 of each

2.5 | Mutational analyses

cycle. Following consolidation, single-agent glasdegib 100 mg admin-

Baseline central laboratory assessments included analysis of 12 genes

istered daily continuously, as maintenance therapy, for a maximum of

frequently mutated in patients with AML or MDS. Additional details

6 cycles (1 cycle = 28 days) was permitted. Patients who completed

can be found in the Supporting Information Materials.

the maximum number of treatment cycles and demonstrated clinical
benefit were allowed to remain on therapy upon agreement between

2.6 | Statistical analyses

the investigator and sponsor.
Study treatment continued until the patient withdrew consent,

The primary endpoint analyses for this study were based on patients

developed unacceptable toxicity, or demonstrated either resistant dis-

who were ≥55 years old. The primary endpoint was CR, with the final

ease during induction or disease progression/relapse after induction.

analysis timing defined as deaths in at least 40 of 60 patients

Patients could proceed to allogeneic stem cell transplant; those who

≥55 years old. However, due to a lower than anticipated death rate, a

did were removed from study treatment and followed for survival.

decision was made to declare the primary completion date and data

The 100 mg glasdegib daily dose could be temporarily interrupted or

cut-off date as January 3, 2017, wherein 38 deaths were reported.

reduced to 50 mg to manage toxicity. After cycle 1, if a toxicity was

A key secondary endpoint was OS. Other secondary endpoints

attributed to the backbone chemotherapy and not to glasdegib, che-

included: disease-specific efficacy endpoints; the type, incidence,

motherapeutics could be delayed or reduced, with continuation of

severity, timing, seriousness and relatedness of AEs; corrected QT

glasdegib. If a patient had a dose reduction for a study drug-related

(QTc) interval; glasdegib PK; and mutational analyses. Exploratory

toxicity, the dose was not to be re-escalated.

endpoints included: CR in patients younger than 55 years and efficacy endpoints based on cytogenetic risk. For AML, cytogenetic risk

2.4 | Assessments
2.4.1 | Clinical activity

was assessed using European Leukemia Net (ELN) Risk Criteria
2010.32 For MDS, the International Prognostic Scoring System
(IPSS) was used.33

Efficacy endpoints were based on investigator assessment, using the

The planned sample size was approximately 70 patients. The

modified International Working Group criteria.30,31 Bone marrow

focus of the primary analysis was patients aged ≥55 years, with

evaluations were performed on day 21 of induction cycle 1, and

60 patients ≥55 years old providing ≥82% power to reject the null

thereafter at the investigator's discretion prior to the next cycle of

hypothesis of CR rate of 54% (cytarabine/daunorubicin alone) if the

chemotherapy. If a second cycle of induction therapy was required, a

true CR rate of the combination with glasdegib is 68%. This allowed a

bone marrow evaluation was performed on day 21 of induction cycle

one-sided type I error rate of 10% under a binomial distribution and

2. Patients underwent bone marrow evaluations on day 21 of the con-

one futility analysis at 2 months after the enrollment of the 30th

solidation final cycle, day 1 of maintenance cycles 3 and 6. A bone

patient. Up to 10 patients <55 years old were to be enrolled for

marrow aspirate was required at end of treatment regardless of when

exploratory purposes.

the patient discontinued the trial, unless the end of treatment was

The full analysis set included all enrolled patients who received

within 14 days of a prior evaluation. All aspirate collections were man-

at least one dose of study medication. The PK analysis population

datory unless deemed inappropriate by the investigator and agreed by

included all treated patients who had at least one PK parameter esti-

the sponsor. For the purposes of calculating response duration, bone

mated. The baseline mutational analysis population included all trea-

marrow collection dates were used as the start/stop dates. Patients

ted patients evaluable for both baseline mutational status and

still in CR/CR with incomplete blood count recovery (CRi)/morpho-

response.

logic leukemia-free state (MLFS) at the most recent bone marrow
assessment were censored at the end of treatment.

Descriptive statistics were used throughout the study unless otherwise stated. For the primary efficacy endpoint and binary efficacy
endpoints, point estimates and 80% confidence intervals (CI) were

2.4.2 | Safety

provided; all were based on investigator assessment data. Time-to-

Safety evaluations included physical examinations, laboratory tests,

event endpoints were summarized using the Kaplan-Meier method.

12-lead electrocardiograms, and AEs, with monitoring graded by the

Median event times and two-sided 80% CIs were provided. Statistical

National Cancer Institute Common Terminology Criteria for Adverse

analyses were performed using SAS version 9.4 (SAS Institute,

Events version 4.0.

Cary, NC).
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TABLE 1

Summary of proportions of patients with
investigator-reported complete remission (full analysis set), by age
group

3.1 | Patients
A total of 71 patients aged ≥55 years (n = 61) or <55 years (n = 10)
were enrolled: 66 patients with AML and five patients with MDS;
69 patients (n = 60/9, aged ≥55/<55 years) were treated and

Total
CR, n (%)
80% CI

a

included in the full analysis set; two patients were enrolled, but not

Cytogenetic risk

treated. Of 69 patients who were treated, six (8.7%) completed treat-

Good/intermediate

ment and 63 (91.3%) patients discontinued treatment (Supporting
Information Figure S1). The main reasons for discontinuations from
study treatments were: insufficient clinical response (n = 29; 42.0%)

CR, n (%)
80% exact CI

a

Poor

Total

≥55 years

<55 years

n = 69

n = 60

n=9

32 (46.4)

24 (40.0)

8 (88.9)

(38.7-54.1)

(31.9-48.1)

(75.5-100.0)

n = 48

n = 41

n=7

26 (54.2)

20 (48.8)

6 (85.7)

(45.0-63.4)

(38.8-58.8)

(68.8-100.0)

n = 19

n = 17

n=2

and “other” (n = 15; 21.7%), with the majority of “other” due to trans-

CR, n (%)

5 (26.3)

3 (17.6)

2 (100.0)

plantation (n = 12/15); 11 (15.9%) patients permanently discontinued

80% exact CIa

(13.4-39.3)

(5.8-29.5)

(100.0-100.0)

study treatments due to treatment-related AEs, which included neu-

Not evaluated

n=2

n=2

n=0

trophil count decreased and pneumonitis (related to daunorubicin and

CR, n (%)

1 (50.0)

1 (50.0)

-

cytarabine); myocarditis (related to daunorubicin and glasdegib); inter-

80% exact CIa

(4.7-95.3)

(4.7-95.3)

-

mittent elevated alanine aminotransferase (ALT) (related to daunorubicin, cytarabine and glasdegib); diarrhea (related to daunorubicin,
cytarabine and glasdegib) and nausea in one patient; gastrointestinal
bleeding and infectious enterocolitis in one patient; adenovirus infection; worsening muscle cramps; epigastric pain; atrial fibrillation; and
elevated aspartate aminotransferase and ALT in one patient.

Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; CR,
complete remission; MDS, myelodysplastic syndromes. For AML, good/
intermediate
cytogenetic
risk = favorable,
intermediate-I
and
intermediate-II risk groups; poor cytogenetic risk = adverse risk group. For
MDS, good/intermediate cytogenetic risk = good and intermediate risk
groups; poor cytogenetic risk = poor risk group. CR included both confirmed and unconfirmed responses for MDS patients.
a
Using normal approximation and CIs are expressed in percentages.

Most patients were male (n = 43; 60.6%) and white (n = 60;
84.5%), with a median age of 64.0 (range 27-75) years. The majority

94 (1-480) days in all patients and 103 (1-480) and 50 (1-268) days

of patients had Eastern Cooperative Oncology Group performance

in patients aged ≥55 years and <55 years, respectively. The median

status 1 (n = 44; 62.0%) and good/intermediate cytogenetic risk (ie,

(range) duration of CR, CRi, or MLFS across all patients was

favorable, intermediate-I, or intermediate-II risk; n = 50; 70.4%)

53 (1-480) days. The number of patients censored for CR duration

(Supporting Information Table S1). Seven (9.9%) patients received

was 16/24 (66.7%) and 5/8 (62.5%) in the groups aged ≥55 and <55

prior hypomethylating agents (decitabine or azacitidine).

years, respectively.

The number of patients starting each cycle was: glasdegib induc-

Median OS was 14.9 (80% CI 13.4-19.3) months, with a

tion, n = 69 (100.0%); re-induction cycle 2, n = 14 (20.3%); consolida-

12-month survival probability of 66.6% (80% CI 58.5-73.4) (Figure 1).

tion, n = 26 (37.7%); and maintenance, n = 15 (21.7%). Of the

Median OS (80% CI) in patients aged ≥55 years and <55 years was

15 patients who received at least 1 cycle of maintenance therapy,

14.7 (13.1-17.7) months and not estimable (NE) (11.0-NE) months,

6 completed 6 cycles, 6 discontinued due to cytogenetic or morpho-

respectively (Figure 1).

logical relapse, 2 discontinued due to AEs (grade 1-2 nausea/diarrhea;

Twenty-four (34.8%) patients received an allogeneic hematopoi-

grade 3 muscle spasms) and one patient refused further treatment

etic cell transplant: 18 aged ≥55 years and 6 aged <55 years. Twelve

after receiving 11 cycles of maintenance. Following discontinuation of

(17.4%) patients discontinued treatment in order to receive a trans-

the study treatment, 72.5% (n = 50) of patients received follow-up

plant: 9 aged ≥55 years and 3 aged <55 years; 12 patients discontin-

systemic therapies, with the majority of patients (n = 39) receiving

ued treatment for other reasons and later received a transplant. After

chemotherapy (Supporting Information Table S2).

censoring for transplant, median OS (80% CI) was 17.7 (14.5-NE)

The median exposure to glasdegib was 48.0 (range 10-501) days.
The mean relative glasdegib dose intensity was 89.6% and the mean
relative chemotherapy dose intensities were 99.2% and 99.1% for
cytarabine and daunorubicin, respectively.

months for all patients, 14.9 (13.4-19.3) months in patients ≥55 years
of age, and NE (NE-NE) in patients <55 years of age (Figure 1).
In patients with AML vs. MDS, the estimated median OS (80% CI)
was 16.3 (13.4-19.4) months vs. 13.0 (11.0-15.6) months (Supporting
Information Table S5). In patients with AML who were aged

3.2 | Clinical activity

≥55 years, median OS (80% CI) was 14.7 (13.1-19.3) months.
Although patient numbers were small, OS in patients aged ≥55 years,

Of the 69 patients, 46.4% (80% CI 38.7-54.1) achieved CR (Table 1).

as well as in patients aged >60 years, compared favorably with esti-

For the primary analysis, CR (80% CI) was reported in 40.0%

mated OS according to ELN risk criteria32: median OS (80% CI) in

(31.9-48.1) of patients aged ≥55 years and 88.9% (75.5-100.0) in

patients with AML aged ≥55 years was NE (NE-NE) in those with

patients aged <55 years; 37 (53.6% [80% CI 45.9-61.3]) patients

favorable risk, 19.3 (13.1-NE) months in those with intermediate-I risk,

overall, 35 (54.7% [80% CI 46.7-62.7]) with AML and 2 (40.0% [80%

13.4 (9.0-14.7) months in those with intermediate-II risk and 8.5

CI 11.9-68.1]) with MDS achieved CR/CRi (Supporting Information

(5.8-12.3) months in patients categorized with adverse risk (Table 2:

Tables S3 and S4). The median (range) duration of CR was

Supportive Information Figure S2).
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(A)
Censored

1.0

Glasdegib 100 mg
+ Cytarabine/daunorubicin

Median OS (80% CI), months
14.9 (13.4–19.3)

Probability of OS

0.8

0.6

0.4

0.2

0.0

0

5

10

15

20

25

30

35

No. at risk 69 68 64 62 60 56 53 52 50 49 45 44 43 40 35 32 31 30 28 28 26 26 26 25 25 25 24 24 21 16 14 12 11 8

5

1

40

45

0

Time (months)
Censored

(B)

Favorable
Intermediate-I
Intermediate-II
Adverse

1.0

Median OS (80% CI), months
NE (NE–NE)
19.4 (14.5–NE)
13.4 (9.0–14.7)
9.7 (5.8–12.3)

Probability of OS

0.8

0.6

0.4

0.2

0.0

No. at risk
Fav
Int-I
Int-II
Adv

0
13
19
13
17

5
13
19
13
17

12
18
12
16

11
18
11
16

10
18
11
15

10
18
10
12

10
10
18
9
10

10
18
9
9

10
18
8
8

10
17
8
8

10
16
7
6

15
10
15
7
6

10
15
7
6

10
14
7
5

10
13
4
5

10
12
2
5

20
10
12
2
5

10
12
2
5

10
11
1
5

10
11
1
5

10
9
1
5

25
10
9
1
5

10
9
1
5

10
9
1
4

10
9
1
4

10
9
1
4

30
10
9
1
3

10
9
1
3

9
7
1
3

7
6
0
2

35

6
5

5
4

4
4

3
2

2
1

1
0

2

2

2

2

2

0

40

45

40

45

0

Time (months)

(C)

1.0
Censored
All patients
Censored for transplant

Probability of OS

0.8

Median OS (80% CI), months
14.7 (13.1–17.7)
14.9 (13.4–19.3)

0.6

0.4

0.2

0.0

0

5

10

15

20

25

30

No. at risk
All patients 60 59 55 53 51 48 45 44 42 41 37 37 37 35 30 27 26 25 23 23 21 21 21 20 20 20 19 19 16 11 9
Censored for 60 59 53 48 43 36 34 31 31 29 25 25 24 23 20 17 17 16 15 15 13 13 13 12 12 12 12 12 10 7 5
transplant

35
7
5

7
5

6
4

4
3

1
1

0
0

Time (months)

A, Kaplan-Meier plot of OS in all patients; B, patients with AML by cytogenetic risk and C, patients aged ≥55 years with and without
censoring for patients receiving a transplant. Adv, adverse; AML, acute myeloid leukemia; CI, confidence interval; NE, not evaluable; Fav,
favorable; Int, intermediate; OS, overall survival [Color figure can be viewed at wileyonlinelibrary.com]

FIGURE 1
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TABLE 2

OS in patients with AML ≥55 years of age and aged >60 years, compared with historical controls
AML cytogenetic risk
Total

Favorable

Intermediate I

Intermediate II

Adverse

Not evaluated

58

12

15

13

16

2

Patients aged ≥55 years with AML
n
a

Deaths , n (%)

36 (62.1)

2 (16.7)

9 (60.0)

10 (76.9)

13 (81.3)

2 (100)

Disease under study

29 (50.0)

1 (8.3)

7 (46.7)

10 (76.9)

10 (62.5)

1 (50.0)

Unknown

4 (6.9)

0

2 (13.3)

0

1 (6.3)

1 (50.0)

Other

11 (19.0)

1 (8.3)

3 (20.0)

2 (15.4)

4 (25.0)

1 (50.0)

Number censored, n (%)

22 (37.9)

10 (83.3)

6 (40.0)

3 (23.1)

3 (18.8)

0

Probability of survival at month 12 (80% CI)b

64.0

82.5

80.0

64.2

37.5

50.0

(55.1-71.6)

(62.0-92.6)

(62.6-89.9)

(42.8-79.3)

(22.4-52.6)

(7.7-82.9)

Median OS (80% CI)c, months

14.7

NE

19.3

13.4

8.5

8.4

(13.1-19.3)

(NE-NE)

(13.1-NE)

(9.0-14.7)

(5.8-12.3)

(0.5-16.3)

Patients aged >60 years with AML
n

44

9

12

11

10

2

Deathsa, n (%)

29 (65.9)

1 (11.1)

9 (75.0)

9 (81.8)

8 (80.0)

2 (100)

Disease under study

23 (52.3)

0

7 (58.3)

9 (81.8)

6 (60.0)

1 (50.0)

Unknown

3 (6.8)

0

2 (16.7)

0

0

1 (50.0)

Other

10 (22.7)

1 (11.1)

3 (25.0)

2 (18.2)

3 (30.0)

1 (50.0)

15 (34.1)

8 (88.9)

3 (25.0)

2 (18.2)

2 (20.0)

0

62.4

88.9

75.0

60.6

30.0

50.0

(52.1-71.1)

(65.4-96.8)

(54.6-87.2)

(38.3-77.0)

(13.4-48.7)

(7.7-82.9)

14.5

NE

15.7

13.4

8.5

8.4

(13.0-17.7)

(NE-NE)

(13.0-19.4)

(7.9-13.7)

(4.0-9.7)

(0.5-16.3)

8.7

14.6

9.5

9.2

4.8

-

(7.8-9.7)

(11.7-17.6)

(7.3-11.7)

(7.1-11.3)

(3.7-5.9)

Number censored, n (%)
Probability of survival at month 12 (80% CI)
Median OS (80% CI)c, months
d

Historical controls (n = 710)

b

32

Median OS (95% CI), months

Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; NE, not estimable; OS, overall survival.
Patients may have multiple reasons for cause of death.
b
Calculated from the product-limit method.
c
Based on the Brookmeyer and Crowley method.
d
Treatment with 7 + 3 schedule.
a

3.3 | Safety
A total of 1824 AEs were reported among all 69 patients. The most
common all-causality AEs (in ≥50% of patients) were diarrhea, febrile
neutropenia, nausea and hypokalemia (Table 3). The most frequently
reported grade > 3 all-causality AEs (in ≥30% of patients) were febrile
neutropenia, anemia and thrombocytopenia; the most common nonhe-

Over the course of the study, 41 (59.4%) deaths were reported;
5 (7.2%) treatment-emergent deaths occurred within 28 days of the
last dose: disease progression (n = 2) and sepsis, pneumonia and septic shock (n = 1 each). One case of sepsis was considered by the
investigator to be treatment-related to combination glasdegib plus
cytarabine/daunorubicin. One (1.4%) and four (5.8%) patients (all aged

matologic grade > 3 all-causality AEs were hypertension, pneumonia

≥55 years) died ≤30 and ≤60 days, respectively, from the first dose of

and sepsis (n = 7 [10.1%] each). The most common treatment-related

study treatments. No patients with CR died while on active treatment.

AEs (in ≥50% of patients) were diarrhea and nausea. The most fre-

Thirty-six (52.2%) deaths occurred during the follow-up period

quently reported grade > 3 treatment-related AEs (≥25% of patients)

(>28 days after the last dose); the main cause among all 69 patients

were febrile neutropenia and anemia. Median (range) investigator-

was progression of the disease under study (n = 30; 43.5%).

reported time to platelet recovery (≥100 000 μL) and neutrophil recov-

AEs of special interests for glasdegib, including muscle spasms,

ery (≥1000 μL) for patients achieving CR (n = 32) was 31.0 (20-82) days

dysgeusia, alopecia, acute kidney injury, or electrocardiogram pro-

and 32.0 (3-95) days, respectively.

longed QTc, were nonserious; the majority were grades 1 or 2, except

Across all patients, 14 (20.3%) and 25 (36.2%) patients perma-

for one case of serious acute kidney injury that was considered not

nently and temporarily, respectively, discontinued study treatments

treatment-related. The grade 3 acute kidney injury (creatinine

(glasdegib and/or cytarabine/daunorubicin) due to AEs; 5 (7.2%)

2.47 mg/dL) occurred after a hypotensive episode that resolved with-

patients had dose reductions due to AEs and 35 (50.7%) patients

out intervention and was considered to be related to analgesics and

reported serious AEs (SAEs). The most frequently reported SAEs (≥5%

dehydration. On the same day, the patient was diagnosed with grade

of patients) were febrile neutropenia, sepsis, and pneumonia, and all

3 acute myocardial infarction (MI); thus, the investigator considered

other SAEs were reported by no more than two patients.

the acute kidney injury to be related to the non-ST-elevation MI event
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TABLE 3

Treatment-emergent all-causality adverse events reported in ≥30% patients (safety analysis set)

n (%)

Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

Total

Any adverse event

0

1 (1.4)

11 (15.9)

52 (75.4)

5 (7.2)

69 (100.0)

Diarrhea

30 (43.5)

18 (26.1)

1 (1.4)

0

0

49 (71.0)

Febrile neutropenia

0

0

42 (60.9)

2 (2.9)

0

44 (63.8)

Nausea

20 (29.0)

18 (26.1)

2 (2.9)

0

0

40 (58.0)

Hypokalemia

19 (27.5)

9 (13.0)

8 (11.6)

1 (1.4)

0

37 (53.6)

Pyrexia

21 (30.4)

9 (13.0)

3 (4.3)

1 (1.4)

0

34 (49.3)

Constipation

23 (33.3)

9 (13.0)

0

0

0

32 (46.4)

Anemia

0

2 (2.9)

26 (37.7)

0

0

28 (40.6)

Decreased appetite

15 (21.7)

10 (14.5)

1 (1.4)

0

0

26 (37.7)

Fatigue

9 (13.0)

13 (18.8)

3 (4.3)

0

0

25 (36.2)

Vomiting

20 (29.0)

5 (7.2)

0

0

0

25 (36.2)

Hyponatremia

16 (23.2)

0

8 (11.6)

0

0

24 (34.8)

Thrombocytopenia

0

1 (1.4)

3 (4.3)

19 (27.5)

0

23 (33.3)

Abdominal pain

11 (15.9)

9 (13.0)

2 (2.9)

0

0

22 (31.9)

Headache

11 (15.9)

9 (13.0)

2 (2.9)

0

0

22 (31.9)

Hypocalcaemia

5 (7.2)

12 (17.4)

5 (7.2)

0

0

22 (31.9)

Edema peripheral

18 (26.1)

4 (5.8)

0

0

0

22 (31.9)

ALT increased

16 (23.2)

1 (1.4)

3 (4.3)

1 (1.4)

0

21 (30.4)

Chills

13 (18.8)

8 (11.6)

0

0

0

21 (30.4)

Safety analysis set included all enrolled patients who received at least one dose of any of the study medications. Patients were counted only once per preferred term in each row. Each count was based on the maximum grade of events. MedDRA (version 19.1) coding dictionary applied. Adverse events were
graded in accordance with National Cancer Institute CTCAE version 4.03.
Abbreviations: ALT, alanine aminotransferase; MedDRA, Medical Dictionary for Regulatory Activities; CTCAE, Common Terminology Criteria for Adverse
Events.

together with severe hypotension. Muscle spasms led to permanent

AML or high-risk MDS. Although the primary objective of demonstrat-

discontinuation of glasdegib in one patient. No clinically significant

ing a ≥54% CR rate in patients aged ≥55 years was not achieved, the

glasdegib-related QTc prolongation was observed.

response rate of 46.4% (80% CI 38.7-54.1) for all patients was within
the range of those reported for other AML therapies (19-76%, with

3.4 | Pharmacokinetics

most values ~40-50%).2,3,32,34–41 This result included CR rates
reported for patients with AML who received standard doses of cytar-

In all, 65 of 69 patients enrolled in the study provided glasdegib
plasma concentration data. Forty-two patients were considered to be
dose compliant and did not receive cytochrome P450 (CYP)3A4 inhibitors around the time of PK sampling (which might have influenced

abine/daunorubicin on the 7 + 3 schedule.4,42 However, comparisons
between trials are limited due to differences in study design and
patient populations, as well as the effect of age and AML risk category
on CR rates.4

glasdegib exposure), and provided steady-state Ctrough parameter data

Glasdegib in combination with cytarabine/daunorubicin has the

on cycle 1 day 10. The observed glasdegib steady-state Ctrough geo-

potential to demonstrate improved OS in patients with AML or high-

metric mean value was 308.7 ng/mL (geometric % coefficient of variance, 74%).

risk MDS. Median OS of 14.9 months was achieved with glasdegib
100 mg combined with cytarabine/daunorubicin in the overall patient
population and was within the range for OS (6.5-24.5 months)

3.5 | Mutational analyses
Fifty patients were included in baseline mutational analyses of bone
marrow and/or peripheral blood with relationship to response. No significant associations were evident between mutational status of any
of the 12 genes analyzed and clinical response (Supporting Information Table S6).

reported in the literature for patients treated with other AML treatment regimens, including a trial of high-dose daunorubicin in older
patients with AML.2–5,32,34,37,38,40–43 Despite the limited sample sizes,
in a post hoc analysis, the median OS compared favorably with historical controls across ELN risk groups.3,32,40–42
Around 24 months, the OS curve for patients 55 years or older
began to plateau and extended to 36 months. These results suggest
that patients who reached this time point (~40% of patients) had a

4 | DISCUSSION

low risk of death thereafter, which may indicate that a subpopulation
of patients in particular derived a survival benefit from glasdegib treat-

This was a phase 2, open-label, international, multicenter, safety and

ment. The survival benefit does not appear to be influenced by trans-

efficacy study wherein glasdegib was administered in combination

plantation, given that OS results with and without censoring for

with cytarabine/daunorubicin in previously untreated patients with

patients who underwent transplant were similar. Longer follow-up
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and, particularly, randomized trials are required to better assess the

Therefore, it will be critical to evaluate the long-term safety of glasde-

possible effect glasdegib may have in improving OS. Responses were

gib and potentially apply similar strategies for AE management in

observed across diverse mutational profiles, suggesting the potential

patients with AML or high-risk MDS.

for broad efficacy of glasdegib in combination with cytarabine/
daunorubicin.

Although this phase 2 study is limited by small patient numbers
and will require validation in a larger prospective trial, the results from

The primary endpoint, CR rate 54%, was based on the CR rate of

this study are encouraging. Glasdegib in combination with cytarabine/

cytarabine/daunorubicin alone, adapted from Burnett et al.44 Given

daunorubicin was well tolerated and was associated with clinical activ-

the unique mechanism of action of glasdegib as an inhibitor of SMO,

ity in untreated patients with AML or high-risk MDS, as reflected by

traditional endpoints such as CR or CR/CRi rate may underestimate

potential prolongation of OS in the context of historical controls

its clinical benefit. For example, preclinical studies have shown that

across all risk groups. CR rates matched historical controls; however,

SMO inhibitors have little direct cytotoxicity on bulk AML blasts and

low rate of relapse and a suggestion of a favorable OS observed in the

would therefore not be expected to have a large effect on CR

current study suggest that the antileukemia effect of glasdegib may

rates.45,46 If glasdegib eliminated AML stem cells, one would expect

be primarily mediated through the elimination of AML stem cells. To

the effect to be primarily on relapse rate and OS. Indeed, despite the

confirm this mechanism, future studies should evaluate the effect of

small patient numbers in this trial, there was encouraging evidence of

glasdegib on MRD-positive disease in the post-remission setting. A

potentially prolonged OS with glasdegib compared with historical

randomized phase 3 trial of glasdegib in combination with chemother-

data. Although the response duration was short in this analysis, it was

apy on a 7 + 3 schedule is ongoing.

impacted by patients who discontinued treatment due to transplant
and, because disease status was not collected during survival followup, it was also derived by censoring patients at the end of treatment
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